A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO)

This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.

Check your eligibility (clinicaltrials.gov)

Questions regarding this trial: 818-748-4723